Skip to main content
Clinical Trials/NCT01885702
NCT01885702Active, not recruitingPhase 1

Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI

Radboud University Medical Center1 site in 1 country25 target enrollmentStarted: October 2010Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
25
Locations
1
Primary Endpoint
Safety and feasibility of vaccination with frameshift-derived neoantigen-loaded DC of CRC patients

Study Overview

Brief Summary

Objectives:

In this Radboud University Nijmegen Medical Centre (RUNMC) initiated study our first objective is to investigate toxicity (safety and feasibility) of vaccination with frameshift-derived neoantigen-loaded DC of CRC patients with an MSI-positive CRC and persons who are known to be carrier of a germline MMR-gene mutation with no signs of disease yet.

The secondary objectives of the study are:

  • to demonstrate that peptide-loaded DC can induce or enhance an immune response to tumor-associated antigen CEA and specific frameshift-derived neoantigens in the study population.
  • to study the pathological and clinical responses, e.g. disease-free survival, determined according to the standard protocol.

Study design:

This study is a phase I/II open-label study.

Study population:

Two groups of adults will be vaccinated:

Group I) CRC patients, who are known to carry a germline MMR-gene mutation and patients with an MSI-positive CRC and yet unknown or negative MMR-gene mutation status.

Group II) persons who are known to be carrier of a germline MMR-gene mutation with no signs of disease yet. All participants need to be HLA-A2.1 positive.

Detailed Description

Rationale of this study:

Ex vivo generated and tumor-antigen-loaded dendritic cells (DC) are currently used in clinical vaccination protocols in cancer patients. DC vaccines are safe, with minimal side effects. Evaluating more than 200 patients treated the past ten years we found that clinical responses measured in several patients directly coincide with specific cytotoxic T cell responses. The majority of studies investigated the therapeutic effects of DC vaccines in late-stage cancer patients with metastasis. In these (heavily) pretreated patients the immune system is compromised. Based on our observations that a specific immune response is indicative for a good clinical outcome we believe that the full potential of these immunostimulatory cells has to be exploited in high-risk patients with low tumor burden or in a precancerous state.

A good clinical model are carriers of a germline mutation in one of the DNA mismatch repair (MMR) genes, such as patients with Lynch syndrome (also known as Hereditary Non-Polyposis Colorectal Cancer or HNPCC). These persons have a lifetime risk of 60-80% for colorectal cancer that has developed within a few years from a precancerous adenoma. The immune system is thought to be of potential great importance as the colorectal cancer in Lynch syndrome is characterized by a strong lymphocyte infiltration, even at the stage of adenomas. In affected cancer lesions, MMR dysfunction results in frameshift mutations at short, repetitive DNA sequences referred to as microsatellites. In coding regions these mutations destroy gene function and have been demonstrated to lead to the production of neopeptides. These neopeptides are: 1) tumor specific, because frameshift mutations only occur in tumor cells and their premalignant progenitors, 2) are very similar between patients, since the same genes are affected by the mismatch repair defect and 3) immunogenic, since cytotoxic T cells (CTL) and helper T cells could be induced in vitro from blood of patients with Lynch syndrome. Similar mechanisms occur in sporadic colon cancer with MMR dysfunction, which represents about 10-15% of all colorectal 2.

Objectives:

In this Radboud University Nijmegen Medical Centre (RUNMC) initiated study our first objective is to investigate toxicity (safety and feasibility) of vaccination with frameshift-derived neoantigen-loaded DC of CRC patients with an MSI-positive CRC and persons who are known to be carrier of a germline MMR-gene mutation with no signs of disease yet.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • histologically documented evidence of CRC (group I) and Lynch syndrome carrier without signs of disease (group II)
  • HLA-A2.1 phenotype is required
  • MSI high tumor
  • WBC >3.0 x 109/l, lymphocytes >0.8 x 109/l, platelets >100 x 109/l, serum crea¬tinine <150 µmol/l, serum bilirubin <25 µmol/l
  • WHO performance status 0-1 (Karnofsky 100-70%)
  • Age 18-75 years
  • Expected adequacy of follow-up
  • Written informed consent

Exclusion Criteria

  • History of malignancy in the past 5 years with the exception of adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix
  • Serious active infections, HbsAg or HIV positive (test only in case of high risk or clinical suspicion)
  • Autoimmune diseases or organ allografts
  • Concomitant use of immunosuppressive drugs
  • Known allergy to shell fish
  • Pregnant or lactating women

Arms & Interventions

MSI-positive CRC patients

Experimental

I) Adjuvant DC vaccinations for MSI-positive CRC patients (n=5)

Intervention: DC vaccination (Biological)

Carriers of germline MMR-gene mutation

Experimental

II) Preventive DC vaccinations for carriers of germline MMR-gene mutation (n=20) withhout manifestation of CRC

Intervention: DC vaccination (Biological)

Outcomes

Primary Outcomes

Safety and feasibility of vaccination with frameshift-derived neoantigen-loaded DC of CRC patients

Time Frame: 5 years

Patients will be followed for toxicity, autoimmunity and immunological response during the study and 2 and 6 months thereafter at the outpatient clinic. Subsequently, follow up will be performed as for standard practice. Toxicity will be assessed using the Clinical Toxicity Criteria NCI CTC version 3.0.

Secondary Outcomes

  • Pathological responses(5 years)
  • Clinical responses, e.g. disease-free survival, determined according to the standard protocol.(5 years)
  • To evaluate whether peptide-loaded DC can induce or enhance an immune response to tumor-associated antigen CEA and specific frameshift-derived neoantigens in the study population(5 years)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Dendritic cell vaccination in patients with Lynch Syndrome or colorectal cancer with MSIhereditary non-polyposis colorectal cancerLynch syndrome100836241001799010027656
NL-OMON39056niversitair Medisch Centrum Sint Radboud25
Active, not recruiting
Phase 1
Dendritic cell vaccination in patients with Lynch Syndrome or colorectal cancer with MSI - DC vaccination in lynch syndrome patientsIn this study our primary objective is to induce or enhance an immune response to tumor antigens in Lynch syndrome mutation carriers (with and without colorectal adenomas or carcinomas) and patients with sporadic colorectal cancer (CRC) showing microsatellite instability (MSI-high), the hallmark of MMR dysfunction, and test the hypothesis that DC vaccination might be effective as prophylactic treatment in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) or Lynch syndrome mutation carriers.
EUCTR2008-005584-33-NLRadboud University Nijmegen Medical Centre25
Completed
Phase 1
Dendritic Cell Vaccine for Children and Adults With SarcomaSoft Tissue SarcomaBone SarcomaSarcoma
NCT01803152Macarena De La Fuente, MD19
Completed
Phase 1
Clinical study of Dendritic Cell Vaccine in patients with Gastroenterological Cancer and Hepato-Biliary-Pancreatic Cancer.Esophageal cancer, Stomach cancer, Colon cancer, HCC, ICC, Bile duct cancer, pancreatic cancer
JPRN-UMIN000005820Department of Gastroenterological Surgery, Tokyo Women&#39;s Medical University100
Recruiting
Not Applicable
A pilot study of dendritic cell vaccination for stage IV melanoma following combination lymphodepleting chemotherapy.Stage IV MelanomaCancer - Malignant melanoma
ACTRN12608000174381niversity of Queensland20